Show simple item record

dc.contributor.authorYap, TAen_US
dc.contributor.authorSmith, ADen_US
dc.contributor.authorFerraldeschi, Ren_US
dc.contributor.authorAl-Lazikani, Ben_US
dc.contributor.authorWorkman, Pen_US
dc.contributor.authorde Bono, JSen_US
dc.date.accessioned2017-11-24T12:31:57Z
dc.date.issued2016-10en_US
dc.identifier.citationNature reviews. Drug discovery, 2016, 15 (10), pp. 699 - 718en_US
dc.identifier.issn1474-1776en_US
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/950
dc.identifier.eissn1474-1784en_US
dc.identifier.doi10.1038/nrd.2016.120en_US
dc.description.abstractCastration-resistant prostate cancer (CRPC) is associated with a poor prognosis and poses considerable therapeutic challenges. Recent genetic and technological advances have provided insights into prostate cancer biology and have enabled the identification of novel drug targets and potent molecularly targeted therapeutics for this disease. In this article, we review recent advances in prostate cancer target identification for drug discovery and discuss their promise and associated challenges. We review the evolving therapeutic landscape of CRPC and discuss issues associated with precision medicine as well as challenges encountered with immunotherapy for this disease. Finally, we envision the future management of CRPC, highlighting the use of circulating biomarkers and modern clinical trial designs.en_US
dc.formatPrint-Electronicen_US
dc.format.extent699 - 718en_US
dc.languageengen_US
dc.language.isoengen_US
dc.rights.urihttp://www.rioxx.net/licenses/all-rights-reserveden_US
dc.subjectAnimalsen_US
dc.subjectHumansen_US
dc.subjectAntineoplastic Agentsen_US
dc.subjectMaleen_US
dc.subjectDrug Discoveryen_US
dc.subjectMolecular Targeted Therapyen_US
dc.subjectTranslational Medical Researchen_US
dc.subjectGenetic Therapyen_US
dc.subjectProstatic Neoplasms, Castration-Resistanten_US
dc.subjectBiomarkers, Tumoren_US
dc.titleDrug discovery in advanced prostate cancer: translating biology into therapy.en_US
dc.typeJournal Article
dcterms.dateAccepted2016-07-22en_US
rioxxterms.versionofrecord10.1038/nrd.2016.120en_US
rioxxterms.licenseref.urien_US
rioxxterms.licenseref.startdate2016-10en_US
rioxxterms.typeJournal Article/Reviewen_US
dc.relation.isPartOfNature reviews. Drug discoveryen_US
pubs.issue10en_US
pubs.notes6 monthsen_US
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Therapeutics
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Therapeutics/Computational Biology and Chemogenomics
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Therapeutics/Medicine Drug Development Unit (de Bono)
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Medicine Drug Development Unit (de Bono)
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Prostate Cancer Targeted Therapy Group
pubs.publication-statusPublisheden_US
pubs.volume15en_US
pubs.embargo.terms6 monthsen_US
icr.researchteamComputational Biology and Chemogenomicsen_US
icr.researchteamMedicine Drug Development Unit (de Bono)en_US
icr.researchteamProstate Cancer Targeted Therapy Groupen_US
dc.contributor.icrauthorWorkman, Paulen_US
dc.contributor.icrauthorDe Bono, Johannen_US
dc.contributor.icrauthorAl-Lazikani, Bissanen_US
dc.contributor.icrauthorYap, Timothyen_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record